Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Seamless, Randomized, Third-Party-Blind, Clinical Trial to Evaluate the Safety and Efficacy of Meplazumab in Addition to Standard of Care for the Treatment of COVID-19 in Hospitalized Adults

NCT04586153 is registered in ClinicalTrials.gov with Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd as lead sponsor.

NCT NCT04586153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04586153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Seamless, Randomized, Third-Party-Blind, Clinical Trial to Evaluate the Safety and Efficacy of Meplazumab in Addition to Standard of Care for the Treatment of COVID-19 in Hospitalized Adults
Lead sponsor
Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
Phase
Phase 2/3
Overall status
Completed
Start date
February 15, 2021
Completion date
December 18, 2022
Enrollment
174 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19